Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal <sup>18</sup>F-FES PET/CT

<div>Experimental design for treatment protocols, <sup>18</sup>F-FES microPET/CT imaging, and immunohistochemistry staining. Vehicle (0.9% sodium chloride, 50 <i>μ</i>l/mouse/week, s.c.), Tan IIA (30 mg/kg, every other day, injected via tail vein), FUL (250 mg/kg, weekly, s.c.), and FUL + Tan IIA combination therapy. The entire period of treatment was 21 days. •: <sup>18</sup>F-FES microPET/CT imaging; <sup>△</sup>IHC staining of ER<i>α</i>.</div>

Contrast Media & Molecular Imaging

fig1

Figure 1

Figure 1: Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal <sup>18</sup>F-FES PET/CT 

Figure 1 | Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal 18F-FES PET/CT 